missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Dextran Sulfate Sodium Salt, Colitis Grade (36,000 to 50,000), MP Biomedicals™
Induces severe colitis (inflammatory bowel disease) in laboratory animals
Brand: MP Biomedicals 0216011025
322.46 EUR valid until 2024-12-31
Use promo code "23894" to get your promotional price.
This item is not returnable.
View return policy
Description
Induces severe colitis (inflammatory bowel disease) in laboratory animals
Dextran sulfate sodium salt, or DSS, is a synthetic sulfated branched polysaccharide derivative of dextran that has multiple uses in biomedical and clinical research. One important property of DSS is to trigger colitis in mice and rats when administered in drinking water. DSS binds to medium-chain-length fatty acids in the colon and induces intestinal inflammation. Colitis-grade DSS (MW = 36,000 to 50,000) from MP Bio is one of the most widely used products based on peer reviewed scientific publications.
- Induces severe colitis (inflammatory bowel disease)
- Highest sulfur content – 19%
- Highest chirality - +104° of specific rotation
- Lowest pH – 6.2 at 1% solution
Specifications
| Dextran Sulfate Sodium Salt | |
| 5 to 7.11 (1% aqueous solution) | |
| Powder | |
| 92°C | |
| MFCD00081551 | |
| 25 g | |
| *-OC[C@H]1O[C@H](OC[C@H]2O[C@H](-*)[C@H](O[*])[C@@H](O[*])[C@@H]2O[*])[C@H](O[*])[C@@H](O-*)[C@@H]1O[*] | |
| 40,000 | |
| Colitis Grade | |
| Plastic Container |
| White | |
| 9011-18-1 | |
| 310°C | |
| (C6H7O5)m(C6H7O5)n | |
| Soluble in water | |
| BLFLLBZGZJTVJG-UHFFFAOYSA-N | |
| Dextran sulfate sodium salt | |
| Used for inducing ulcerative colitis in animals and extensively to study colon cancer developing in relation to colonic inflammation | |
| <10% |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Unless specified otherwise, MP Biomedical's products are for research or further manufacturing use only, not for direct human use.
Spot an opportunity for improvement?Share a Content Correction